ChiCTR-INR-16009598
正在进行
/
/
/
2016-10-25
/
/
冠心病
基于智能手机的家庭心脏康复和冠心病患者二级预防的随机对照研究
基于智能手机的家庭心脏康复和冠心病患者二级预防的随机对照研究
The aim of the clinical trial is to assess the effects of smartphone-based cardiac rehabilitation and secondary prevention program on the short-term and long-term outcomes of post-PCI CHD patients, as well as its effects on improvement of quality of life, enhancing management of risk factors and medication, increasing cost benefits and reducing hospital readmissions.
随机平行对照
治疗新技术
The Project Manager will be supplied with one randomization envelope for each participant. It is the responsibility of the Project Manager to ensure that these randomization envelopes are safely stored, but readily available to the relevant staff. Once patients have signed the Consent Form, they will provided with a
/
Curtin University PhD research funding
/
300
/
2016-05-06
2019-05-05
/
Eligible participants will be patients diagnosed with coronary heart disease and received PCI. Inclusion criteria are that the participant must: Diagnosed by a clinician, have met criteria for diagnosis of CHD; Received PCI therapy during this admission; Aged between 18-70 years; Have an active smartphone, and have sufficient Chinese language proficiency to reading, speaking and listening; Able to operate smartphone for the purposes of trial; Living with at least one caregiver or guardian in the household; Presence of normal hemodynamics with a resting ejection fraction ≥ 50%; Able to individually consent; Not participating in any other clinical trial.；
请登录查看Unable to be involved in clinical follow up and treatment; Unable to operate smartphone for the purpose of the trial (eg, vision, hearing, cognitive or dexterity impairment); Had no experience with WeChat application; Have no internet connection at residence and smartphone Wi-Fi connection; Have contra-indication to CR.；
请登录查看Curtin University
/
医药经济报2025-12-12
医学新视点2025-12-12
上海拓界生物医药2025-12-12
绽妍JUYOU2025-12-12
隆门资本2025-12-12
信邦制药2025-12-12
君实医学2025-12-12
触界生物2025-12-12
标新生物GLUETACS2025-12-12
兽药资讯2025-12-12
400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科 中国医疗人才网 医药招商网
